Oxford Cannabinoid Technologies Holdings (OCTP) – the company developing prescription cannabinoid medicines – is expanding its research and development plans into oncology. The decision comes after it identified a potential first in class immunotherapy agent for solid tumour treatment.
https://www.pharmatimes.com/news/cannabinoid_company_expands_into_oncology_1494574